ID   SPRE_HUMAN              Reviewed;         261 AA.
AC   P35270; A8K741; D6W5H2; Q53GI9; Q9UBB1;
DT   01-FEB-1994, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1994, sequence version 1.
DT   18-JUN-2025, entry version 224.
DE   RecName: Full=Sepiapterin reductase;
DE            Short=SPR;
DE            EC=1.1.1.153 {ECO:0000269|PubMed:10350607, ECO:0000269|PubMed:11443547};
GN   Name=SPR;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Liver;
RX   PubMed=1883349; DOI=10.1016/0006-291x(91)91352-d;
RA   Ichinose H., Katoh S., Sueoka T., Titani K., Fujita K., Nagatsu T.;
RT   "Cloning and sequencing of cDNA encoding human sepiapterin reductase -- an
RT   enzyme involved in tetrahydrobiopterin biosynthesis.";
RL   Biochem. Biophys. Res. Commun. 179:183-189(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=8440319; DOI=10.1006/excr.1993.1027;
RA   Maier J., Schott K., Werner T., Bacher A., Ziegler I.;
RT   "Detection of a novel sepiapterin reductase mRNA: assay of mRNA in various
RT   cells and tissues of various species.";
RL   Exp. Cell Res. 204:217-222(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Salivary gland;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Kidney;
RA   Suzuki Y., Sugano S., Totoki Y., Toyoda A., Takeda T., Sakaki Y.,
RA   Tanaka A., Yokoyama S.;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P.,
RA   Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L.,
RA   Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A.,
RA   Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J.,
RA   Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M.,
RA   Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T.,
RA   Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S.,
RA   Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S.,
RA   Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C.,
RA   Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M.,
RA   Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C.,
RA   Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J.,
RA   Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X.,
RA   Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M.,
RA   Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H.,
RA   Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2 and
RT   4.";
RL   Nature 434:724-731(2005).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Pancreas;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=9792819; DOI=10.1006/bbrc.1998.9503;
RA   Ohye T., Hori T.A., Katoh S., Nagatsu T., Ichinose H.;
RT   "Genomic organization and chromosomal localization of the human sepiapterin
RT   reductase gene.";
RL   Biochem. Biophys. Res. Commun. 251:597-602(1998).
RN   [9]
RP   CATALYTIC ACTIVITY, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=10350607; DOI=10.1016/s0167-4838(99)00054-0;
RA   Fujimoto K., Ichinose H., Nagatsu T., Nonaka T., Mitsui Y., Katoh S.;
RT   "Functionally important residues tyrosine-171 and serine-158 in sepiapterin
RT   reductase.";
RL   Biochim. Biophys. Acta 1431:306-314(1999).
RN   [10]
RP   KINETIC PARAMETERS, PHOSPHORYLATION AT SER-213, AND MUTAGENESIS OF SER-213.
RX   PubMed=11825621; DOI=10.1016/s0167-4838(01)00300-4;
RA   Fujimoto K., Takahashi S.Y., Katoh S.;
RT   "Mutational analysis of sites in sepiapterin reductase phosphorylated by
RT   Ca2+/calmodulin-dependent protein kinase II.";
RL   Biochim. Biophys. Acta 1594:191-198(2002).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-103, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 5-261 IN COMPLEX WITH NADP.
RG   Structural genomics consortium (SGC);
RT   "Crystal structure of human sepiapterin reductase.";
RL   Submitted (FEB-2009) to the PDB data bank.
RN   [15]
RP   VARIANTS DRDSPRD 119-GLN--LYS-261 DEL AND GLY-150, AND CHARACTERIZATION OF
RP   VARIANT DRDSPRD GLY-150.
RX   PubMed=11443547; DOI=10.1086/321970;
RA   Bonafe L., Thony B., Penzien J.M., Czarnecki B., Blau N.;
RT   "Mutations in the sepiapterin reductase gene cause a novel
RT   tetrahydrobiopterin-dependent monoamine-neurotransmitter deficiency without
RT   hyperphenylalaninemia.";
RL   Am. J. Hum. Genet. 69:269-277(2001).
RN   [16]
RP   VARIANT DRDSPRD LEU-163.
RX   PubMed=16650784; DOI=10.1016/j.ymgme.2006.03.010;
RA   Abeling N.G.G.M., Duran M., Bakker H.D., Stroomer L., Thoeny B., Blau N.,
RA   Booij J., Poll-The B.T.;
RT   "Sepiapterin reductase deficiency an autosomal recessive DOPA-responsive
RT   dystonia.";
RL   Mol. Genet. Metab. 89:116-120(2006).
RN   [17]
RP   VARIANT DRDSPRD GLY-150.
RX   PubMed=17159114; DOI=10.1212/01.wnl.0000247274.21261.b4;
RA   Friedman J., Hyland K., Blau N., MacCollin M.;
RT   "Dopa-responsive hypersomnia and mixed movement disorder due to sepiapterin
RT   reductase deficiency.";
RL   Neurology 67:2032-2035(2006).
CC   -!- FUNCTION: Catalyzes the final one or two reductions in tetra-
CC       hydrobiopterin biosynthesis to form 5,6,7,8-tetrahydrobiopterin.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=L-erythro-7,8-dihydrobiopterin + NADP(+) = L-sepiapterin +
CC         NADPH + H(+); Xref=Rhea:RHEA:18953, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:43029, ChEBI:CHEBI:57783, ChEBI:CHEBI:58349,
CC         ChEBI:CHEBI:194527; EC=1.1.1.153;
CC         Evidence={ECO:0000269|PubMed:10350607, ECO:0000269|PubMed:11443547};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:18955;
CC         Evidence={ECO:0000269|PubMed:10350607, ECO:0000269|PubMed:11443547};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(6R)-L-erythro-5,6,7,8-tetrahydrobiopterin + 2 NADP(+) = 6-
CC         pyruvoyl-5,6,7,8-tetrahydropterin + 2 NADPH + 2 H(+);
CC         Xref=Rhea:RHEA:32627, ChEBI:CHEBI:15378, ChEBI:CHEBI:57783,
CC         ChEBI:CHEBI:58349, ChEBI:CHEBI:59560, ChEBI:CHEBI:136564;
CC         EC=1.1.1.153; Evidence={ECO:0000305|PubMed:10350607};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:32629;
CC         Evidence={ECO:0000305|PubMed:10350607};
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=14.3 uM for sepiapterin {ECO:0000269|PubMed:10350607,
CC         ECO:0000269|PubMed:11825621};
CC         KM=10 uM for NADPH {ECO:0000269|PubMed:10350607,
CC         ECO:0000269|PubMed:11825621};
CC         Note=kcat is 1.1 sec(-1) with sepiapterin as substrate
CC         (PubMed:10350607). kcat is 1.1 sec(-1) with NADPH as substrate
CC         (PubMed:10350607). {ECO:0000269|PubMed:10350607};
CC   -!- SUBUNIT: Homodimer. {ECO:0000269|Ref.14}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm.
CC   -!- PTM: In vitro phosphorylation of Ser-213 by CaMK2 does not change
CC       kinetic parameters. {ECO:0000269|PubMed:11825621}.
CC   -!- DISEASE: Dystonia, DOPA-responsive, due to sepiapterin reductase
CC       deficiency (DRDSPRD) [MIM:612716]: A form of DOPA-responsive dystonia.
CC       In the majority of cases, patients manifest progressive psychomotor
CC       retardation, dystonia and spasticity. Cognitive anomalies are also
CC       often present. The disease is due to severe dopamine and serotonin
CC       deficiencies in the central nervous system caused by a defect in BH4
CC       synthesis. Dystonia is defined by the presence of sustained involuntary
CC       muscle contractions, often leading to abnormal postures.
CC       {ECO:0000269|PubMed:11443547, ECO:0000269|PubMed:16650784,
CC       ECO:0000269|PubMed:17159114}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the sepiapterin reductase family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M76231; AAA60314.1; -; mRNA.
DR   EMBL; AK291856; BAF84545.1; -; mRNA.
DR   EMBL; AK222942; BAD96662.1; -; mRNA.
DR   EMBL; AC092630; AAY15035.1; -; Genomic_DNA.
DR   EMBL; CH471053; EAW99757.1; -; Genomic_DNA.
DR   EMBL; CH471053; EAW99758.1; -; Genomic_DNA.
DR   EMBL; BC017310; AAH17310.1; -; mRNA.
DR   EMBL; AB017547; BAA34534.1; -; Genomic_DNA.
DR   CCDS; CCDS1920.1; -.
DR   PIR; JQ1176; JQ1176.
DR   RefSeq; NP_003115.1; NM_003124.5.
DR   PDB; 1Z6Z; X-ray; 2.50 A; A/B/C/D/E/F=5-261.
DR   PDB; 4HWK; X-ray; 2.40 A; A/B/C/D=1-261.
DR   PDB; 4J7U; X-ray; 2.44 A; A/B/C/D=1-261.
DR   PDB; 4J7X; X-ray; 2.60 A; A/B/F/J=1-261.
DR   PDB; 4XWY; X-ray; 2.35 A; A/B/C/D=1-261.
DR   PDB; 4Z3K; X-ray; 2.35 A; A/B/C/D=1-261.
DR   PDB; 6I6C; X-ray; 1.72 A; A/B=1-261.
DR   PDB; 6I6F; X-ray; 1.94 A; A/B=1-261.
DR   PDB; 6I6P; X-ray; 1.62 A; A/B=1-261.
DR   PDB; 6I6T; X-ray; 1.79 A; A/B=1-261.
DR   PDB; 6I6V; X-ray; 1.43 A; A/B=1-261.
DR   PDB; 6I79; X-ray; 1.63 A; A/B=1-261.
DR   PDB; 6USN; X-ray; 2.77 A; A/B/C/D=1-261.
DR   PDB; 7DSF; X-ray; 1.80 A; A/B=1-261.
DR   PDBsum; 1Z6Z; -.
DR   PDBsum; 4HWK; -.
DR   PDBsum; 4J7U; -.
DR   PDBsum; 4J7X; -.
DR   PDBsum; 4XWY; -.
DR   PDBsum; 4Z3K; -.
DR   PDBsum; 6I6C; -.
DR   PDBsum; 6I6F; -.
DR   PDBsum; 6I6P; -.
DR   PDBsum; 6I6T; -.
DR   PDBsum; 6I6V; -.
DR   PDBsum; 6I79; -.
DR   PDBsum; 6USN; -.
DR   PDBsum; 7DSF; -.
DR   AlphaFoldDB; P35270; -.
DR   SMR; P35270; -.
DR   BioGRID; 112575; 111.
DR   FunCoup; P35270; 878.
DR   IntAct; P35270; 8.
DR   MINT; P35270; -.
DR   STRING; 9606.ENSP00000234454; -.
DR   BindingDB; P35270; -.
DR   ChEMBL; CHEMBL3988583; -.
DR   DrugBank; DB03886; Biopterin.
DR   DrugBank; DB04275; N-acetylserotonin.
DR   DrugBank; DB03461; Nicotinamide adenine dinucleotide phosphate.
DR   DrugBank; DB02637; Oxaloacetate Ion.
DR   GuidetoPHARMACOLOGY; 3020; -.
DR   GlyGen; P35270; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; P35270; -.
DR   PhosphoSitePlus; P35270; -.
DR   SwissPalm; P35270; -.
DR   BioMuta; SPR; -.
DR   DMDM; 464801; -.
DR   jPOST; P35270; -.
DR   MassIVE; P35270; -.
DR   PaxDb; 9606-ENSP00000234454; -.
DR   PeptideAtlas; P35270; -.
DR   ProteomicsDB; 55020; -.
DR   Pumba; P35270; -.
DR   Antibodypedia; 31290; 378 antibodies from 30 providers.
DR   DNASU; 6697; -.
DR   Ensembl; ENST00000234454.6; ENSP00000234454.5; ENSG00000116096.7.
DR   GeneID; 6697; -.
DR   KEGG; hsa:6697; -.
DR   MANE-Select; ENST00000234454.6; ENSP00000234454.5; NM_003124.5; NP_003115.1.
DR   UCSC; uc002sik.3; human.
DR   AGR; HGNC:11257; -.
DR   CTD; 6697; -.
DR   DisGeNET; 6697; -.
DR   GeneCards; SPR; -.
DR   GeneReviews; SPR; -.
DR   HGNC; HGNC:11257; SPR.
DR   HPA; ENSG00000116096; Low tissue specificity.
DR   MalaCards; SPR; -.
DR   MIM; 182125; gene.
DR   MIM; 612716; phenotype.
DR   OpenTargets; ENSG00000116096; -.
DR   Orphanet; 70594; Dopa-responsive dystonia due to sepiapterin reductase deficiency.
DR   VEuPathDB; HostDB:ENSG00000116096; -.
DR   eggNOG; KOG1204; Eukaryota.
DR   GeneTree; ENSGT00440000033609; -.
DR   HOGENOM; CLU_010194_2_11_1; -.
DR   InParanoid; P35270; -.
DR   OMA; FKGWTLY; -.
DR   OrthoDB; 153074at2759; -.
DR   PAN-GO; P35270; 2 GO annotations based on evolutionary models.
DR   PhylomeDB; P35270; -.
DR   BioCyc; MetaCyc:HS03979-MONOMER; -.
DR   BRENDA; 1.1.1.153; 2681.
DR   PathwayCommons; P35270; -.
DR   Reactome; R-HSA-1474151; Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation.
DR   Reactome; R-HSA-203615; eNOS activation.
DR   SABIO-RK; P35270; -.
DR   SignaLink; P35270; -.
DR   SIGNOR; P35270; -.
DR   BioGRID-ORCS; 6697; 15 hits in 1161 CRISPR screens.
DR   ChiTaRS; SPR; human.
DR   EvolutionaryTrace; P35270; -.
DR   GeneWiki; Sepiapterin_reductase; -.
DR   GenomeRNAi; 6697; -.
DR   Pharos; P35270; Tchem.
DR   PRO; PR:P35270; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   RNAct; P35270; protein.
DR   Bgee; ENSG00000116096; Expressed in mucosa of transverse colon and 175 other cell types or tissues.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005739; C:mitochondrion; HTP:FlyBase.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0004033; F:aldo-keto reductase (NADPH) activity; TAS:UniProtKB.
DR   GO; GO:0050661; F:NADP binding; TAS:UniProtKB.
DR   GO; GO:0004757; F:sepiapterin reductase (NADP+) activity; ISS:UniProtKB.
DR   GO; GO:0006809; P:nitric oxide biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0006729; P:tetrahydrobiopterin biosynthetic process; IBA:GO_Central.
DR   CDD; cd05367; SPR-like_SDR_c; 1.
DR   FunFam; 3.40.50.720:FF:000259; Sepiapterin reductase; 1.
DR   Gene3D; 3.40.50.720; NAD(P)-binding Rossmann-like Domain; 1.
DR   InterPro; IPR051721; Biopterin_syn/organic_redct.
DR   InterPro; IPR036291; NAD(P)-bd_dom_sf.
DR   InterPro; IPR002347; SDR_fam.
DR   InterPro; IPR006393; Sepiapterin_red.
DR   NCBIfam; TIGR01500; sepiapter_red; 1.
DR   PANTHER; PTHR44085; SEPIAPTERIN REDUCTASE; 1.
DR   PANTHER; PTHR44085:SF2; SEPIAPTERIN REDUCTASE; 1.
DR   Pfam; PF00106; adh_short; 1.
DR   PRINTS; PR00081; GDHRDH.
DR   SUPFAM; SSF51735; NAD(P)-binding Rossmann-fold domains; 1.
DR   neXtProt; NX_P35270; -.
DR   PharmGKB; PA36087; -.
DR   TreeFam; TF326358; -.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Cytoplasm; Disease variant; Dystonia; NADP;
KW   Oxidoreductase; Phosphoprotein; Proteomics identification;
KW   Reference proteome.
FT   CHAIN           1..261
FT                   /note="Sepiapterin reductase"
FT                   /id="PRO_0000072149"
FT   BINDING         14..20
FT                   /ligand="NADP(+)"
FT                   /ligand_id="ChEBI:CHEBI:58349"
FT                   /evidence="ECO:0000269|Ref.14"
FT   BINDING         42..43
FT                   /ligand="NADP(+)"
FT                   /ligand_id="ChEBI:CHEBI:58349"
FT                   /evidence="ECO:0000269|Ref.14"
FT   BINDING         69..70
FT                   /ligand="NADP(+)"
FT                   /ligand_id="ChEBI:CHEBI:58349"
FT                   /evidence="ECO:0000269|Ref.14"
FT   BINDING         157..158
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250"
FT   BINDING         170
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250"
FT   BINDING         174
FT                   /ligand="NADP(+)"
FT                   /ligand_id="ChEBI:CHEBI:58349"
FT                   /evidence="ECO:0000250"
FT   BINDING         199
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250"
FT   BINDING         201..206
FT                   /ligand="NADP(+)"
FT                   /ligand_id="ChEBI:CHEBI:58349"
FT                   /evidence="ECO:0000269|Ref.14"
FT   BINDING         257
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         1
FT                   /note="N-acetylmethionine"
FT                   /evidence="ECO:0000250|UniProtKB:P18297"
FT   MOD_RES         32
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P18297"
FT   MOD_RES         103
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         213
FT                   /note="Phosphoserine; by CaMK2; in vitro"
FT                   /evidence="ECO:0000269|PubMed:11825621"
FT   VARIANT         119..261
FT                   /note="Missing (in DRDSPRD)"
FT                   /evidence="ECO:0000269|PubMed:11443547"
FT                   /id="VAR_085775"
FT   VARIANT         150
FT                   /note="R -> G (in DRDSPRD; loss of sepiapterin reductase
FT                   activity; dbSNP:rs104893665)"
FT                   /evidence="ECO:0000269|PubMed:11443547,
FT                   ECO:0000269|PubMed:17159114"
FT                   /id="VAR_058007"
FT   VARIANT         163
FT                   /note="P -> L (in DRDSPRD; dbSNP:rs104893666)"
FT                   /evidence="ECO:0000269|PubMed:16650784"
FT                   /id="VAR_058008"
FT   MUTAGEN         213
FT                   /note="S->A: Abolishes phosphorylation by CaMK2. No effect
FT                   on kinetic parameters."
FT                   /evidence="ECO:0000269|PubMed:11825621"
FT   CONFLICT        10
FT                   /note="C -> R (in Ref. 4; BAD96662)"
FT                   /evidence="ECO:0000305"
FT   TURN            2..5
FT                   /evidence="ECO:0007829|PDB:6I6V"
FT   STRAND          7..14
FT                   /evidence="ECO:0007829|PDB:6I6V"
FT   HELIX           18..30
FT                   /evidence="ECO:0007829|PDB:6I6V"
FT   STRAND          36..42
FT                   /evidence="ECO:0007829|PDB:6I6V"
FT   HELIX           44..56
FT                   /evidence="ECO:0007829|PDB:6I6V"
FT   HELIX           57..59
FT                   /evidence="ECO:0007829|PDB:4J7X"
FT   STRAND          62..67
FT                   /evidence="ECO:0007829|PDB:6I6V"
FT   HELIX           73..84
FT                   /evidence="ECO:0007829|PDB:6I6V"
FT   STRAND          94..99
FT                   /evidence="ECO:0007829|PDB:6I6V"
FT   HELIX           111..113
FT                   /evidence="ECO:0007829|PDB:6I6V"
FT   HELIX           117..127
FT                   /evidence="ECO:0007829|PDB:6I6V"
FT   HELIX           129..141
FT                   /evidence="ECO:0007829|PDB:6I6V"
FT   STRAND          149..155
FT                   /evidence="ECO:0007829|PDB:6I6V"
FT   HELIX           158..160
FT                   /evidence="ECO:0007829|PDB:6I6V"
FT   HELIX           168..187
FT                   /evidence="ECO:0007829|PDB:6I6V"
FT   STRAND          191..197
FT                   /evidence="ECO:0007829|PDB:6I6V"
FT   STRAND          200..203
FT                   /evidence="ECO:0007829|PDB:6I6V"
FT   HELIX           204..212
FT                   /evidence="ECO:0007829|PDB:6I6V"
FT   HELIX           216..228
FT                   /evidence="ECO:0007829|PDB:6I6V"
FT   HELIX           234..247
FT                   /evidence="ECO:0007829|PDB:6I6V"
FT   STRAND          254..257
FT                   /evidence="ECO:0007829|PDB:6I6V"
SQ   SEQUENCE   261 AA;  28048 MW;  9C9BF76212826F47 CRC64;
     MEGGLGRAVC LLTGASRGFG RTLAPLLASL LSPGSVLVLS ARNDEALRQL EAELGAERSG
     LRVVRVPADL GAEAGLQQLL GALRELPRPK GLQRLLLINN AGSLGDVSKG FVDLSDSTQV
     NNYWALNLTS MLCLTSSVLK AFPDSPGLNR TVVNISSLCA LQPFKGWALY CAGKAARDML
     FQVLALEEPN VRVLNYAPGP LDTDMQQLAR ETSVDPDMRK GLQELKAKGK LVDCKVSAQK
     LLSLLEKDEF KSGAHVDFYD K
//
